Trial Profile
A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms FOSTAMR
- 01 Oct 2021 Planned End Date changed from 1 Feb 2021 to 31 Jul 2024.
- 01 Oct 2021 Planned primary completion date changed from 1 Feb 2021 to 31 Jul 2024.
- 07 Jun 2020 This trial is suspended, according to European Clinical Trials Database record.